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Perfusion processes have been employed for approximately 25 years in the biopharmaceutical industry for the 
production of labile biotherapeutics, at high dilution rates and low residence times. In the last 5 years, due to the 
higher volumetric productivities, more compact bioreactors and possibility of integration to continuous 
downstream processing, perfusion has become increasingly popular also for the production of stable 
biopharmaceuticals, such as monoclonal antibodies (mAbs), thus allowing for process strategies involving 
higher residence times in the bioreactors. Viable cell densities (VCD) higher than 100 million cells per mL have 
been reached in the last years in perfusion processes using tangential filtration systems, such as TFF and ATF, 
as cell retention devices. However, these very high cell density cultures have usually been achieved through the 
application of high dilution rates, requiring large medium preparation facilities, large footprint for medium and 
harvest storage, and large capture chromatography systems to process the harvested supernatant. 
The aim of the present study was to develop perfusion processes for stable biotherapeutics operating at low 
cell-specific perfusion rates, as a way to minimize liquid handling in perfusion-based plants. The CHO-DP12 cell 
line (ATCC, USA) secreting a humanized mAb was used as model system. Cells were cultured in stirred-tank 
bioreactors, and processes based on two cell retention devices were evaluated: a CS10 inclined lamella settler 
(Biotechnology Solutions, USA) and an ATF2 (Repligen, USA). A chemically defined, animal-derived component 
free medium (TC-LECC, Xell AG, Germany) was used as basal medium. In some runs, a concentrated nutrient 
solution commercialized to be used as feed for fed-batch processes (TCX2D, Xell AG, Germany) was used to 
fortify the basal medium, aiming at a reduction of the cell-specific perfusion rate (CSPR). 
In a one-month perfusion process using the inclined settler and fed with basal medium, steady states lasting one 
week each were established at CSPRs progressively decreasing from 46 to 18 pL/cell/day. This allowed to 
sustain a VCD of approximately 50 million cells per mL at viabilities >90% at a dilution rate (harvest + bleed) of 
approximately 0.9 vvd. Under these conditions, a metabolic shift towards lactate consumption was observed, 
and an increase in mAb titer was achieved for the lower CSPRs. Based on these results, the same feeding 
strategy (basal medium alone, using a CSPR of approximately 18 pL/cell/d) was employed in a one-month ATF-
based perfusion process with the aim of establishing very high cell density processes. A peak VCD of 136 
million cells per mL was obtained, and a smooth perfusion operation at an average of 120 million cells per mL 
was successfully established, with viabilities higher than 87% over the entire run (Fig. 1). In comparison with the 
pioneering work by Clincke et al. (2013, doi: 10.1002/btpr.1704), the CSPR used in the present work is 
approximately 3-fold lower than theirs, and no issues regarding pumping the cell suspension in and out of the 
ATF cartridge were experienced, in spite of the similar high cell densities achieved. In a further attempt to 
decrease even more the CSPR, we investigated a gradual fortification of the basal medium by adding a 
concentrated feed solution in increasing 
proportions (up to 40% by volume), which 
enabled a reduction of CSPR down to 13 
pL/cell/d in an ATF-based perfusion run kept 
at 40 million cells per mL for over 30 days. 
However, a progressive decrease in cell 
viability, especially at the highest nutrient 
concentrations tested, was observed, being 
possibly associated to the osmolality increase 
caused by the gradual medium fortification. 
Overall, these results have shown the 
feasibility of achieving very high cell densities 
at CSPRs below 20 pL/cell/d using basal 
medium only, and further studies are currently 
ongoing to further improve the process. 
